{"id":2723,"date":"2026-08-27T11:00:00","date_gmt":"2026-08-27T15:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2723"},"modified":"2026-08-27T19:24:19","modified_gmt":"2026-08-27T23:24:19","slug":"crispr-off-target-effects-vary-by-cell-type-and-organ-study-finds","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2723","title":{"rendered":"CRISPR Off-Target Effects Vary by Cell Type and Organ, Study Finds"},"content":{"rendered":"

Companies:<\/strong> AstraZeneca \/ Integrated DNA Technologies · Finding:<\/strong> CRISPR Off-Targets Vary by Cell and Organ · Publication:<\/strong> Nature Communications · Date:<\/strong> August 26, 2026<\/p>\n

\"20260827_AstraZeneca_IDT_CRISPR_Safety_Technology_and_Modalities\"<\/p>\n

Summary<\/h4>\n

An AstraZeneca- and Integrated DNA Technologies-led Nature Communications study found that CRISPR-Cas9 off-target mutations and balanced translocations can differ across individual cells, differentiated cell types and mouse organs, even under the same guide and nuclease context. Single-cell analysis recovered rare events missed by bulk measurements, and tissue context altered indel patterns, repair-pathway use and translocation propensity. The work strengthens the case for organ-specific and high-sensitivity safety testing but does not quantify patient risk or invalidate carefully designed therapeutic guides.<\/p>\n

What Happened<\/h4>\n

The investigators combined rhAmpSeq targeted sequencing with clonally expanded edited mouse embryos and embryonic stem cells, whole-genome amplification of single cells, chromatin-accessibility and transcriptomic profiling, differentiated cell types and inducible-Cas9 mouse models. A deliberately promiscuous PCSK9 guide served as a stress-test control; a more specific guide represented a therapeutic-like design. Individual clones showed unique off-target and balanced-translocation profiles, including events not detected in bulk pools; for the specific guide, low-frequency off-target events emerged at six sites under higher-sensitivity single-cell analysis, but no balanced translocations were detected. Casgevy- and FANCF-directed ribonucleoproteins produced no detectable off-targets in the tested HSPC-clone panel. Across mouse organs, the same editing system produced distinct off-target spectra, microhomology-mediated repair use and indel patterns, with lung, colon and spleen showing more larger deletions and greater microhomology-mediated end joining at commonly edited sites than pancreas and kidney; organ experiments used four biological replicates per group and an inducible transgenic system that bypassed real-world delivery constraints.<\/p>\n

Deep Analysis<\/h4>\n

Bulk assays can average away rare cell-specific events, especially when edited cells are lost during culture. For ex-vivo HSPC and T-cell medicines, a rare structural event in a self-renewing or highly expanded clone can matter even when population frequency is low, so the study supports layered nomination, sensitive validation and clonal or single-cell interrogation when feasible. Tissue-specific outcomes complicate in-vivo editing because the target organ, biodistribution, chromatin state and local repair programs may change both frequency and type of unintended event, meaning safety packages based only on liver, blood or an easy surrogate tissue may not represent every exposed organ. The model intentionally used a promiscuous guide to reveal mechanism and an inducible transgene to standardize exposure; those features amplify discoverability but limit direct clinical extrapolation, as the negative Casgevy\/FANCF clone results illustrate.<\/p>\n

Company and Product Background<\/h4>\n

CRISPR-Cas9 uses a guide RNA to direct a nuclease to a matching genomic sequence, where a double-strand break is repaired by endogenous pathways; mismatched genomic sites can also be cut, creating small insertions or deletions, large structural variants or translocations. Sequence similarity, chromatin accessibility, nuclease exposure and DNA-repair context influence these outcomes. Ex-vivo editing allows release testing before infusion but can create clonal-selection risks during manufacturing; in-vivo editing avoids cell harvest and transplantation but exposes multiple tissues according to delivery biodistribution. High-fidelity nucleases, guide optimization, transient ribonucleoprotein or mRNA exposure and tissue-selective delivery are complementary risk controls.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Detection<\/td>\nSingle-cell workflow revealed rare off-target edits and translocations missed in bulk pools<\/td>\n<\/tr>\n
Context<\/td>\nEditing and repair outcomes differed across cells and organs<\/td>\n<\/tr>\n
Therapeutic-Like Guide<\/td>\nMore specific PCSK9 guide produced low-frequency edits, no balanced translocations detected<\/td>\n<\/tr>\n
Clinical Controls<\/td>\nNo off-targets detected for Casgevy- or FANCF-directed RNPs in tested HSPC clones<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Current bulk-centric safety workflows may underestimate rare, context-specific editing events, particularly for in-vivo programs, and this study provides a methodological basis for improving safety testing sensitivity across the gene-editing field.<\/p>\n

Bear case:<\/strong> The study is primarily a stress-test of assay sensitivity using an intentionally promiscuous guide and engineered mouse exposure, and does not materially change risk for optimized clinical guides, as shown by the negative findings for Casgevy- and FANCF-directed RNPs.<\/p>\n

InSilens Take<\/h4>\n

The study adds a practical warning: the same CRISPR cut can produce different rare outcomes depending on the cell and organ, and bulk testing may not capture every clone. It does not show that approved or clinical-stage editing products are unsafe; its immediate value is methodological, arguing for safety packages designed around intended and off-target tissues, orthogonal assays and the biological consequences of rare clones.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

An AstraZeneca- and Integrated DNA Technologies-led Nature Communications study found that CRISPR-Cas9 off-target mutations and balanced translocations can differ across individual cells, differentiated cell types and mouse organs, even under the same guide and…<\/p>\n","protected":false},"author":1,"featured_media":2732,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[366,369],"class_list":["post-2723","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-crispr","tag-gene-editing"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2723"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2723\/revisions"}],"predecessor-version":[{"id":2739,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2723\/revisions\/2739"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2732"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}